Dr. Sperling is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham & Women's Hospital
Boston, MA 02115Phone+1 617-732-8060Fax+1 617-264-5212
Education & Training
- Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 1992 - 1995
- Brigham and Women's HospitalInternship, Internal Medicine, 1991 - 1992
- Harvard Medical SchoolClass of 1991
Certifications & Licensure
- MA State Medical License 1995 - 2026
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Dominantly Inherited Alzheimer Network (DIAN) Start of enrollment: 2009 Jan 01
- Implications of Amyloid Pathology Start of enrollment: 2008 Nov 01
- Evolution of Memory Related Activity Start of enrollment: 2006 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1773 citationsA conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseFrank Jessen, Rebecca E. Amariglio, Martin P.J. van Boxtel, Monique M.B. Breteler, Mathieu Ceccaldi
Alzheimer's & Dementia. 2014-11-01 - 29 citationsAccelerating Alzheimer's therapeutic development: The past and future of clinical trials.Adam L Boxer, Reisa Sperling
Cell. 2023-10-26 - 37 citationsVariant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.Jasmeer P Chhatwal, Stephanie A Schultz, Eric McDade, Aaron P Schultz, Lei Liu
The Lancet. Neurology. 2022-02-01
Journal Articles
- Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer DiseaseReisa Sperling, Michael S Rafii, Gary Romano, JAMA Neurology
- Short-Term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive ImpairmentJeffrey M Burns, Keith A Johnson, Reisa A Sperling, Jason Karlawish, JAMA Neurology
- Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer DiseaseHyun-Sik Yang, Reisa Sperling, Matthew Schrag, Richard Mayeux, JAMA Neurology
- Join now to see all
Authored Content
- Short-Term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive ImpairmentAugust 2020
- Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer DiseaseJune 2020
- Association of Factors with Elevated Amyloid Burden in Clinically Normal Older IndividualsApril 2020
- Sex, Amyloid, and APOE ε4 and Risk of Cognitive Decline in Preclinical Alzheimer's Disease: Findings from Three Well-Characterized CohortsMay 2018
- Join now to see all
Press Mentions
- Genes Known to Increase the Risk of Alzheimer's May Actually Be an Inherited Form of the Disorder, Researchers SayJune 27th, 2024
- Sex-Specific Parental History of Alzheimer’s Could Identify at-Risk AdultsJune 17th, 2024
- Scientists Discover New Type of Early-Onset Alzheimer’s Caused by GenesMay 6th, 2024
- Join now to see all
Grant Support
- Evolution Of Memory Related FMRI Activation Over The Course Of MCI And ADNational Institute On Aging2012
- Implications Of Amyloid Deposition In Clinically Normal Older IndividualsNational Institute On Aging2009–2012
- Mentoring Imaging Research In Early ADNational Institute On Aging2010–2011
- Impact Of Amyloid On The Aging BrainNational Institute On Aging2010–2011
- Evolution Of Memory-Related FMRI Activation Over The Course Of MCI And ADNational Institute On Aging2006–2010
- Alzheimer'S Disease Neuroimaging Initiative (ADNI)National Center For Research Resources2007–2008
- Trial Of Simvastatin To Slow The Progression Of Alzheimer'S DiseaseNational Center For Research Resources2005–2008
- Trial Of Simvastation To Slow The Progression Of Alzheimer'S DiseaseNational Center For Research Resources2006
- Reducing Homocysteine To Slow Cognitive Decline In Alzheimer'S DiseaseNational Center For Research Resources2006
- Reducing Homocysteine To Slow Cognitive Decline In Alzheimer'SNational Center For Research Resources2005
- Assessment Measures For Alzheimer'S Disease: Primary Prevention TrialsNational Center For Research Resources2005
- Trial Of Simvastatin To Slow Progression Of Alzheimer'SNational Center For Research Resources2004
- Efficacy And Safety Of Ly451395 In Probable Alzheimer'SNational Center For Research Resources2004
- Face-Name Association: FMRI Studies In Aging &Mild ADNational Institute Of Neurological Disorders And Stroke2000–2004
- Functional Magnetic Resonance Imaging (FMRI)National Institute On Aging2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: